Study Of GW679769 In Major Depressive Disorder

Phase 2

Completed

• Conditions: Depressive Disorder, Major; Major Depressive Disorder (MDD)

• Registration Number: NCT00102492
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Study First Submitted QC: 2005-01-28
• Study First Submitted: 2005-01-29
• Study First Posted: 2005-01-31
• Primary Completion: 2006-09
• Study Completion: 2006-09
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-14
• Last Update Posted: 2015-04-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 356

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.

Secondary Outcome Measures

Name	Time	Method
CGI, HAM-A, QUIDS, SDS, MOS-12 Sleep Module, LSEQ, Safety and Tolerability, PK/PD

Trial Locations

Locations (1)

GSK Investigational Site; 🇨🇦 Sherbrooke, Quebec, Canada